One nurse's goal: Making small print a big deal

More than 1.3 million Americans fall victim to medication errorsand, for one Ohio nurse, it's a case of enough is enough. Janeen Jones, BSN, RN, has developed the MagniMed line of lighted magnification systems to make small print on medication labels easier to read.

The Institute for Safe Medication Practice, for example, recommends using light and magnification tools on all medication carts and automated dispensing units to help healthcare professionals when reading medication labels and packaging. With many caregivers having similar problems, Jones set out to develop a solution to reduce such medication errors.

Jones’s company, Janeil Enterprises, developed its line of MagniMed lighted magnification systems to assist healthcare professionals in reading small fonts on medication labels. After a year of use at a Cleveland hospital pharmacy, 94 percent of professional said the MagniMed products helped in reading medication labels, which could protect patients from dangerous medication errors.

"We want to work with healthcare providers and with the companies building and selling medication carts and cabinets," said Jones. "Our systems will help staff read the fine print and patients everywhere will be safer."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.